Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101062 · ClinicalTrials.gov registry record · Phase 2
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00101062: Clinical Trial Phase 2 study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00101062 is a Phase 2 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101062, a Phase 2 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving letrozole with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well letrozole and celecoxib work in treating postmenopausal women with locally advanced or metastatic breast cancer.
Interventions
- DRUG letrozole
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Why NCT00101062 stopped before completion
NCT00101062 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which letrozole is the first listed.
NCT00101062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00101062 about?
NCT00101062 is a clinical study titled "Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow t...
What is the current status of trial NCT00101062?
This trial is currently terminated. It is a Phase 2 study. The study started on 2004-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00101062?
The interventions under investigation include: letrozole (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00101062?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia